Current therapeutic approaches for Parkinson's disease (PD) are based around treatments
that alleviate symptoms but do not slow or prevent disease progression. As such, alternative …

In orchestrating cell signaling, facilitating plasma membrane repair, supervising protein
secretion, managing waste elimination, and regulating energy consumption, lysosomes are …

Abstract Mutations in the Leucine Rich Repeat Protein Kinase 2 gene (LRRK2) are genetic
predispositions for Parkinson's Disease, of which the G2019S (GS) missense mutation is the …

Mutations in Leucine-rich repeat kinase 2 (LRRK2) are a risk factor for and a cause of
sporadic and familial Parkinson's disease (PD), respectively. These mutations are some of …

Background Inflammatory bowel disease (IBD) and Parkinson's disease (PD) are chronic
disorders that have been suggested to share common pathophysiological processes …

Pathogenic mutations in LRRK2 cause Parkinson's disease (PD). The G2019S variant is the
most common, which results in abnormally high kinase activity. Compounds that target …

Introduction Nearly two decades after leucine rich repeat kinase 2 (LRRK2) was discovered
as a genetic determinant of Parkinson's disease (PD), LRRK2 has emerged a priority …

Introduction Parkinson's disease (PD) is a complex disorder with vast clinical heterogeneity.
Recent genetic, imaging and clinical evidence suggest that there are multiple subtypes of …

Over the last decades, research on the pathobiology of neurodegenerative diseases has
greatly evolved, revealing potential targets and mechanisms linked to their pathogenesis …

Alterations to the LRRK2 gene have been associated with Parkinson's disease and alcohol
consumption in animals and humans. Furthermore, these disorders are strongly related to …